Skip to main content

Table 3 Results of subgroup analysis among included studies

From: A meta-analysis of the impact of COVID-19 on liver dysfunction

Subgroup Studies sample size Included (N) (study/control) Chi-square (df) P value Pooled overall heterogeneity SMD (95% CI) (I2)
Non-survivors vs survivors ALS (levels)
 Age≥70 2 86/432 0.72 (1) .001 3.25 (2.95-3.56) 0
Severe vs non-severe ALT (levels)
 Number of non-severe≥100 2 115/364 0.06 (1) .001 3.42 (3.12-3.73) 0
Severe vs non-severe AST (events)
 Age≥60 6 379/1284 11.17 (5) .001 5.09 (3.26-7.94) 55
Severe vs non-severe AST (levels)
 Age≥60 3 81/236 2.21 (2) .001 3.98 (3.54-4.43) 10
Severe vs non-severe TBIL (levels)
 Number of non-severe≥100 2 88/364 0.62 (1) .001 1.49 (1.24-1.74) 0
 Number of non-severe<100 4 125/236 5.14 (3) .001 0.93 (0.61-1.25) 42